These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

831 related items for PubMed ID: 20426497

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT, Tsuji BT.
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
    Zhanel GG, Trapp S, Gin AS, DeCorby M, Lagacé-Wiens PR, Rubinstein E, Hoban DJ, Karlowsky JA.
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
    Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA.
    Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
    [Abstract] [Full Text] [Related]

  • 8. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S, Kuti JL, Nicolau DP.
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [Abstract] [Full Text] [Related]

  • 9. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V, Zeitlinger M.
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [Abstract] [Full Text] [Related]

  • 10. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
    Roberts KD, Sulaiman RM, Rybak MJ.
    Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [Abstract] [Full Text] [Related]

  • 12. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF, Seguin DL, Belley A, Moeck G.
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
    [Abstract] [Full Text] [Related]

  • 13. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B, Sarkar C, Schachter J.
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [Abstract] [Full Text] [Related]

  • 14. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ, Drew RH.
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [Abstract] [Full Text] [Related]

  • 15. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F.
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [Abstract] [Full Text] [Related]

  • 16. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW, Carver PL, DePestel DD.
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [Abstract] [Full Text] [Related]

  • 17. A new lipoglycopeptide: telavancin.
    Nannini EC, Stryjewski ME.
    Expert Opin Pharmacother; 2008 Aug; 9(12):2197-207. PubMed ID: 18671473
    [Abstract] [Full Text] [Related]

  • 18. Oritavancin: an investigational lipoglycopeptide antibiotic.
    Karaoui LR, El-Lababidi R, Chahine EB.
    Am J Health Syst Pharm; 2013 Jan 01; 70(1):23-33. PubMed ID: 23261897
    [Abstract] [Full Text] [Related]

  • 19. Telavancin: a novel lipoglycopeptide antimicrobial agent.
    Attwood RJ, LaPlante KL.
    Am J Health Syst Pharm; 2007 Nov 15; 64(22):2335-48. PubMed ID: 17989443
    [Abstract] [Full Text] [Related]

  • 20. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C.
    Expert Opin Investig Drugs; 2009 Apr 15; 18(4):521-9. PubMed ID: 19335280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.